SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients
Additional focus on lifestyle management, self-management education and support emphasized
New study shows metformin is not associated with an increased risk of acidosis in patients with type 2 diabetes and an eGFR of 30 to 60 mL/min/1.73 m2.
Relative risk of end-stage renal disease was 0.13 in those diagnosed in 1995-2011 versus 1965-1979.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
Use of the glucagon-like peptide-1 receptor agonist lowered 24-hour urinary albumin excretion rate by 32% over 12 weeks versus placebo.
Findings in large cohort of patients with diabetes over 4 years of follow-up.
AGEs improve RFL prediction in American-Indians with type 2 diabetes.
No change in overall prevalence from 1988 to 2014; decrease in albuminuria, increase in reduced eGFR.
Incident or worsening nephropathy was observed in 12.7% of patients receiving empagliflozin compared with 18.8% of those receiving placebo.
Length of time spent in remission inversely related to risk of microvascular disease.
Renal function decline is independent factor for cardiovascular risk in patients with type 2 diabetes.
Diabetic nephropathy lesions may develop prior to the onset of clinical findings.
Increase in prevalence from 2002-2013, with highest prevalence among those aged 12 to less than 18 years.
Higher urinary potassium excretion, not sodium excretion, tied to lower risk of primary end point.
AKI, albuminuria, eGFR considered separately or together can predict adverse outcomes in diabetes.
Nonalbuminuric chronic kidney disease was linked to increases in all-cause and cardiovascular mortality, but not albuminuria or end-stage renal disease.
Older patients with more diabetes complications have greater cognitive decline, study finds.
Increased uric acid levels were correlated with decreased HbA1c and increased prevalence of diabetic kidney disease, study finds.
Intense glycemic control was significantly linked to higher risks of cardiovascular and all-cause mortality
Among the increased risks, women with the disease had an 86% higher chance of dying from cardiovascular disease than men.
Researchers in the Netherlands report results from an autopsy study of diabetic nephropathy patients.
Researchers find an independent association in a study of Japanese patients with type 2 diabetes.
Public health efforts needed to ensure adequate access to ophthalmologists.
The drug maintained kidney function in mice with diabetic nephropathy.
A trial of a gluten-free diet presents no inherent risk for patients starting to exhibit microvascular damage.
Among Canadian diabetics, end-stage renal disease is almost three times more likely to development among First Nation adults.
ACE inhibitor plus ARB failed to slow disease progression but increased acute kidney injury risk.
Renal and Urology News Articles
- Novel Albuminuria Endpoints May Improve CKD Progression Trials
- Comorbidities Adversely Linked to Cancer Trial Participation
- Global Demand for Bladder Cancer Treatment Threatens Supply in 2019
- Opioids Now More Deadly for Americans Than Traffic Accidents
- New Predictor of In-Hospital Acute Kidney Injury Identified
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)